PPARG and breast carcinoma: Nevertheless, the present finding clearly demonstrate an antagonistic effect on breast cancer cell proliferation when treated with the combination of γ-tocotrienol and PPARγ agonists, and provides strong evidence that increased expression of PPARγ is a negative indicator for breast cancer responsiveness to anticancer therapy.